Cytokinetics, Incorporated $CYTK Shares Acquired by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. grew its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) by 6.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 215,952 shares of the biopharmaceutical company’s stock after buying an additional 13,512 shares during the period. Pinnacle Associates Ltd. owned 0.17% of Cytokinetics worth $14,233,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Nisa Investment Advisors LLC raised its holdings in Cytokinetics by 2.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 13,050 shares of the biopharmaceutical company’s stock valued at $860,000 after acquiring an additional 345 shares during the last quarter. AMI Asset Management Corp lifted its stake in Cytokinetics by 3.8% in the 3rd quarter. AMI Asset Management Corp now owns 14,800 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 539 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in Cytokinetics by 71.5% in the 3rd quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 191 shares in the last quarter. Nvwm LLC boosted its holdings in shares of Cytokinetics by 5.2% during the 3rd quarter. Nvwm LLC now owns 9,600 shares of the biopharmaceutical company’s stock worth $633,000 after purchasing an additional 477 shares during the last quarter. Finally, Sanders Morris Harris LLC acquired a new position in shares of Cytokinetics during the 3rd quarter worth approximately $1,549,000.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on Cytokinetics, providing continued analyst support for the company’s pipeline and commercial prospects. HC Wainwright rating report
• Positive Sentiment: Cytokinetics scheduled its third-quarter results for November 4, 2026, followed by a management conference call. The report will provide an important update on financial performance, aficamten commercialization and the company’s outlook. Cytokinetics third-quarter results announcement
• Neutral Sentiment: The company granted inducement awards covering 60,465 shares through stock options and 40,084 restricted stock units to 29 new employees. The grants support hiring but could modestly dilute existing shareholders over time. Cytokinetics inducement grants announcement
• Negative Sentiment: BofA Securities reduced its price target to $81 from $85 while maintaining a Neutral rating, signaling more limited near-term conviction even though the target remains above recent trading levels. BofA Securities price-target update
• Negative Sentiment: Wall Street Zen lowered Cytokinetics to a Sell rating, adding to concerns about valuation, execution and the company’s continuing losses. Wall Street Zen downgrade
• Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares for approximately $224,000. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, its bearish signaling value is limited, but it adds to the recent pattern of insider sales. SEC insider transaction filing

Cytokinetics Price Performance

Shares of CYTK stock opened at $62.86 on Thursday. The firm’s 50-day moving average is $69.38 and its two-hundred day moving average is $73.21. Cytokinetics, Incorporated has a 12 month low of $54.30 and a 12 month high of $88.31. The company has a market capitalization of $7.82 billion, a PE ratio of -8.71 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same quarter in the previous year, the firm earned ($1.12) earnings per share. The business’s revenue for the quarter was down 57.1% compared to the same quarter last year. Sell-side analysts forecast that Cytokinetics, Incorporated will post -5.97 EPS for the current year.

Analysts Set New Price Targets

CYTK has been the subject of a number of analyst reports. Barclays upped their price target on Cytokinetics from $95.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Wall Street Zen cut Cytokinetics from a “hold” rating to a “sell” rating in a report on Tuesday. Truist Financial lifted their price objective on Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. William Blair started coverage on Cytokinetics in a research note on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Needham & Company LLC boosted their price objective on Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $105.44.

Insider Buying and Selling

In other Cytokinetics news, EVP Andrew Callos sold 14,000 shares of Cytokinetics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total value of $1,118,320.00. Following the sale, the executive vice president owned 58,555 shares in the company, valued at $4,677,373.40. The trade was a 19.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Blum sold 97,926 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total value of $6,789,209.58. Following the completion of the transaction, the chief executive officer directly owned 385,320 shares in the company, valued at approximately $26,714,235.60. This trade represents a 20.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 191,426 shares of company stock worth $13,543,855. Company insiders own 2.60% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.